Wildon Farwell - Mar 7, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Mar 7, 2024
Transactions value $
-$256,585
Form type
4
Date filed
3/11/2024, 09:52 PM
Previous filing
Feb 28, 2024
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Sale -$216K -8.36K -5.13% $25.80 155K Mar 7, 2024 Direct F1, F2, F3
transaction DYN Common Stock Sale -$40.8K -1.56K -1.01% $26.20 153K Mar 7, 2024 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021 and November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.51 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 Included 128,010 unvested RSUs.
F4 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $26.23, inclusive.